1. Home
  2. MBAI vs BIVI Comparison

MBAI vs BIVI Comparison

Compare MBAI & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.44

Market Cap

10.3M

Sector

N/A

ML Signal

N/A

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.66

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBAI
BIVI
Founded
2004
2013
Country
Israel
United States
Employees
85
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.3M
11.5M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
MBAI
BIVI
Price
$1.44
$1.66
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
64.2K
101.5K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.29
$0.88
52 Week High
$3.92
$9.09

Technical Indicators

Market Signals
Indicator
MBAI
BIVI
Relative Strength Index (RSI) 42.95 57.62
Support Level $1.30 $1.17
Resistance Level $1.83 $1.78
Average True Range (ATR) 0.10 0.15
MACD -0.03 0.01
Stochastic Oscillator 27.45 73.26

Price Performance

Historical Comparison
MBAI
BIVI

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: